All patients
Age < 65y (younger) Age > 65y BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male PD-L1 < 1% PD-L1 > 1%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - L2 - all population, pembrolizumab (10mg/kg) 2 weeks vs. immune chekpoint inhibitors, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-006 (2 week), 2015 0.63 [0.47; 0.84]
0.63 [0.47 ; 0.84 ] KEYNOTE-006 (2 week), 2015 1 0% 557 NA not evaluable deaths (OS) (extension)detailed results KEYNOTE-006 (2 week), 2015 0.68 [0.53; 0.87]
0.68 [0.53 ; 0.87 ] KEYNOTE-006 (2 week), 2015 1 0% 557 NA not evaluable PFS (extension)detailed results KEYNOTE-006 (2 week), 2015 0.61 [0.50; 0.75]
0.61 [0.50 ; 0.75 ] KEYNOTE-006 (2 week), 2015 1 0% 557 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-006 (2 week), 2015 0.58 [0.46; 0.73]
0.58 [0.46 ; 0.73 ] KEYNOTE-006 (2 week), 2015 1 0% 557 NA not evaluable objective responses (ORR)detailed results KEYNOTE-006 (2 week), 2015 3.77 [2.43; 5.86]
3.77 [2.43 ; 5.86 ] KEYNOTE-006 (2 week), 2015 1 0% 557 NA not evaluable STRAE (any grade)detailed results KEYNOTE-006 (2 week), 2015 0.67 [0.41; 1.09]
0.67 [0.41 ; 1.09 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable STRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable TRAE (any grade)detailed results KEYNOTE-006 (2 week), 2015 1.62 [1.07; 2.46]
1.62 [1.07 ; 2.46 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.84 [0.54; 1.30]
0.84 [0.54 ; 1.30 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
1.84 [0.06 ; 55.23 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-006 (2 week), 2015 0.74 [0.39; 1.40]
0.74 [0.39 ; 1.40 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 1.85 [0.17; 20.50]
1.85 [0.17 ; 20.50 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.04; 5.09]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Chills TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.19 [0.06; 0.58]
0.19 [0.06 ; 0.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.32; 2.66]
0.92 [0.32 ; 2.66 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
0.46 [0.02 ; 13.75 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.30 [0.03; 2.95]
0.30 [0.03 ; 2.95 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 2.78 [0.29; 26.92]
2.78 [0.29 ; 26.92 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
0.46 [0.02 ; 13.75 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
0.23 [0.01 ; 5.10 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
1.84 [0.06 ; 55.23 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
0.23 [0.01 ; 5.10 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
0.23 [0.01 ; 5.10 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
0.46 [0.02 ; 13.75 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.06; 14.80]
0.92 [0.06 ; 14.80 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
0.46 [0.02 ; 13.75 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
0.46 [0.02 ; 13.75 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
0.46 [0.02 ; 13.75 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
0.92 [0.02 ; 46.58 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
1.84 [0.06 ; 55.23 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
0.46 [0.02 ; 13.75 ] KEYNOTE-006 (2 week), 2015 1 0% 534 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 03:40 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 69
- treatments: 577